“Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer” (2021) Biomolecules and Biomedicine, 21(2), pp. 198–207. doi:10.17305/bjbms.2020.4746.